Royalty Pharma plc (RPRX)

Royalty Pharma plc (RPRX) public financial performance, SEC filing summary, and valuation metrics.

Financial highlights

Net Income: 294690000 usd (2026-03-31)
Operating Income: 563038000 usd (2026-03-31)
Revenue: 594992000 usd (2026-03-31)
Revenue: 2261152000 usd (2025-12-31)
Operating Income: 1559518000 usd (2025-12-31)
Net Income: 770947000 usd (2025-12-31)
Revenue: 578812000 usd (2025-09-30)
Operating Income: 427156000 usd (2025-09-30)
Net Income: 288217000 usd (2025-09-30)
Net Income: 30176000 usd (2025-06-30)
Operating Income: 209799000 usd (2025-06-30)
Revenue: 550418000 usd (2025-06-30)
Operating Income: 534182000 usd (2025-03-31)
Net Income: 238349000 usd (2025-03-31)
Revenue: 539490000 usd (2025-03-31)
Operating Income: 1292444000 usd (2024-12-31)
Revenue: 2149422000 usd (2024-12-31)
Net Income: 858983000 usd (2024-12-31)
Net Income: 543987000 usd (2024-09-30)
Revenue: 533166000 usd (2024-09-30)